A novel apoA-I mutation (L178P) leads to endothelial dysfunction, increased arterial wall thickness, and premature coronary artery disease
G. Kees Hovingh(Novo Nordisk (Denmark)), John J.P. Kastelein(QRx Pharma (United States)), Marie‐Pierre Dubé(Montreal Heart Institute), Michael R. Hayden(University of British Columbia), Aeilko H. Zwinderman(Amsterdam Neuroscience), Robin P.F. Dullaart(University Medical Center Groningen), Radjesh J. Bisoendial(Amsterdam UMC Location University of Amsterdam), Eric de Groot(Amsterdam UMC Location Vrije Universiteit Amsterdam), Erik S.G. Stroes(Amsterdam University Medical Centers), Johannes H.M. Levels(Amsterdam UMC Location University of Amsterdam), Wilma Petersen(Radboud University Nijmegen), Alison Brownlie(Howard Hughes Medical Institute), Jan Albert Kuivenhoven(University Medical Center Groningen)
Cited by 130
Related Papers
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
|New England Journal of Medicine|2017|9.1k
Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews
|Journal of Clinical Epidemiology|2005|3.3k
Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: Consensus Statement of the European Atherosclerosis Society
|European Heart Journal|2013|2.7k
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
|New England Journal of Medicine|2023|2.6k
Lipoprotein(a) as a cardiovascular risk factor: current status
|European Heart Journal|2010|1.8k